Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 414

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs)

Cooper, Bethany M., Iegre, Jessica, O' Donovan, Daniel H., Ölwegård Halvarsson, Maria, Spring, David R.·2021·Chemical Society Reviews
DOI 10.1039/d0cs00556h
Open this paper in CoChat — free account

Abstract

A tutorial review showcasing how peptide–drug conjugates can offer the versatility needed for a successful drug discovery approach, their problems and future opportunities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1039/d0cs00556h

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Bethany M. Cooper
Bethany M. CooperCC-BY · From the PDF
Daniel H. O'Donovan
Daniel H. O'DonovanCC-BY · From the PDF
Jessica Iegre
Jessica IegreCC-BY · From the PDF
Maria O ¨ lwegård Halvarsson
Maria O ¨ lwegård HalvarssonCC-BY · From the PDF
Fig. 1 A schematic to represent the journey of an orally administrated peptide through the gastrointestinal tract.
Fig. 1 A schematic to represent the journey of an orally administrated peptide through the gastrointestinal tract.CC-BY · From the PDF
David R. Spring
David R. SpringCC-BY · From the PDF
Fig. 2 Different methods used to improve the enzymatic and chemical stability of peptides including: cyclisations and peptide stapling, formulations, moving away from proteinogenic amino acids and chemical modifications.
Fig. 2 Different methods used to improve the enzymatic and chemical stability of peptides including: cyclisations and peptide stapling, formulations, moving away from proteinogenic amino acids and chemical modifications.CC-BY · From the PDF
Fig. 3 The structures of Liraglutide and Semaglutide.
Fig. 3 The structures of Liraglutide and Semaglutide.CC-BY · From the PDF
Fig. 4 A schematic representation of how a targeted therapeutic (green square) is specific for the tumour cells in comparison to a non-targeted therapeutic (blue triangle).
Fig. 4 A schematic representation of how a targeted therapeutic (green square) is specific for the tumour cells in comparison to a non-targeted therapeutic (blue triangle).CC-BY · From the PDF
Image 10
CC-BY · From the PDF
Fig. 6 Lu and co-workers stapled RGD peptide to modify a Paclitaxel loaded PEG-PLA micelle. 31
Fig. 6 Lu and co-workers stapled RGD peptide to modify a Paclitaxel loaded PEG-PLA micelle. 31CC-BY · From the PDF
Fig. 7 An antibody-drug conjugate construct with a cleavable pH sensitive N -acyl hydrazine linker.
Fig. 7 An antibody-drug conjugate construct with a cleavable pH sensitive N -acyl hydrazine linker.CC-BY · From the PDF
Fig. 8 A schematic of a peptide-drug conjugate with an enzyme cleavable dipeptide linker and para -aminobenzyl carbamate spacer.
Fig. 8 A schematic of a peptide-drug conjugate with an enzyme cleavable dipeptide linker and para -aminobenzyl carbamate spacer.CC-BY · From the PDF
Fig. 9 The cleavage mechanism for an arylsulfate linker by Bargh et al. 38
Fig. 9 The cleavage mechanism for an arylsulfate linker by Bargh et al. 38CC-BY · From the PDF
Fig. 10 Structures of payloads used within the peptide-drug conjugate field.
Fig. 10 Structures of payloads used within the peptide-drug conjugate field.CC-BY · From the PDF
Fig. 11 (A) The internalisation mechanism of action where the PDC is cleaved within the lysosome. (B) The PDC is cleaved outside of the cell and the cytotoxin diffuses into the cell.
Fig. 11 (A) The internalisation mechanism of action where the PDC is cleaved within the lysosome. (B) The PDC is cleaved outside of the cell and the cytotoxin diffuses into the cell.CC-BY · From the PDF
Fig. 12 A schematic to represent a photothermal therapy (PTT) both inside and outside the tumour cells by Zhang and co-workers. In the schematic the grey circle represents a Cu sulphide nanoparticles, loaded with a peptide-drug conjugate that is irradiated with near infrared (NIR) light. 44
Fig. 12 A schematic to represent a photothermal therapy (PTT) both inside and outside the tumour cells by Zhang and co-workers. In the schematic the grey circle represents a Cu sulphide nanoparticles, loaded with a peptide-drug conjugate that is irradiated with near infrared (NIR) light. 44CC-BY · From the PDF
Fig. 13 The structures of bicycle-toxin conjugates BT5528, BT8009 and BT1718 developed by Bicycle Therapeutics. 46,47
Fig. 13 The structures of bicycle-toxin conjugates BT5528, BT8009 and BT1718 developed by Bicycle Therapeutics. 46,47CC-BY · From the PDF
Fig. 14 The structure of the peptide-dendrimer conjugate by Gu and coworkers to deliver Doxorubicin. 49
Fig. 14 The structure of the peptide-dendrimer conjugate by Gu and coworkers to deliver Doxorubicin. 49CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 4

  1. He, 2019, Asian J. Pharm. Sci., 15, 19
  2. Theratechnologies Inc., New Data Show Theratechnologies’ SORT1+ Technology Is Effective in Many Treatment-Resistant Cancers, https://www.theratech.com/wp-content/uploads/2020/06/Press-release-AACR-June-22-EN-FINAL.pdf , accessed 11 September 2020
  3. Shi, 2012, Int. J. Nanomed., 7, 1613
  4. Rotin, 1986, Cancer Res., 46, 2821

Cited by

See all 414

Metadata

Authors
Cooper, B. M., Iegre, J., O' Donovan, D. H., Ölwegård Halvarsson, M., & Spring, D. R.
Affiliations
  • Department of Chemistry
  • Oncology R&D
  • Medicinal Chemistry
ORCID
Venue
Chemical Society Reviews
Publisher
Royal Society of Chemistry (RSC)
Published
2021
Volume
50
Issue
3
Pages
1480-1494
ISSN
  • 0306-0012
  • 1460-4744
DOI
10.1039/d0cs00556h
Cited by
414
References
40
Language
en
Licence
creativecommons.org/licenses/by/3.0/ (vor)
Funders
Engineering and Physical Sciences Research Council (G102522)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs). https://app.cochat.ai/papers/10.1039/d0cs00556h
The paper
Cooper, B. M., Iegre, J., O' Donovan, D. H., Ölwegård Halvarsson, M., & Spring, D. R. (2021). Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs). Chemical Society Reviews. https://doi.org/10.1039/d0cs00556h

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.